Objective: Although postmenopausal (post-M) women have behavioral and biological risk factors for HIV infection, the activity of preexposure prophylaxis (PrEP) agents in older adults has not been well studied. Design: We used an ex-vivo approach to compare the tissue concentrations of tenofovir (TFV) diphosphate (TFVdp) and emtricitabine (FTC) triphosphate (FTCtp) in cervical tissues from premenopausal (pre-M) and post-M women. Method: Cervical explants from 16 pre-M and 11 post-M women were incubated in 10-300 μg/ml TFV or FTC for 24 h. Explants were then snap frozen in liquid nitrogen and stored until analysis. TFVdp and FTCtp were quantified using tandem liquid chromatography-mass spectrometry. Results: Active metabolite concentrations of TFVdp were more than nine-fold lower in post-M explants (P < 0.05). The percentage of TFV converted to TFVdp in pre-M explants was 0.0038 [below the limit of quantification (BLQ)-0.5886] compared with 0.0004 (BLQ-0.0706) in post-M explants. The majority of FTCtp concentrations were BLQ. For both TFVdp and FTCtp, there was a trend for more unquantifiable concentrations in post-M vs. pre-M (TFV: 38 vs. 21%, P = 0.2; FTC: 71 vs. 52%, P = 0.2). Conclusion: These findings could have implications in the use of nucleotide-based PrEP strategies targeted to older women. If validated in vivo, lower exposures of active nucleoside/tide metabolites could mean post-M women need higher doses of TFV-based PrEP to achieve protective efficacy.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Jan 2 2018|
Bibliographical noteFunding Information:
The work was financially supported by the Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota and the Deborah E Powell Women’s Center, University of Minnesota. Tissue specimens were collected under the University of Minnesota BioNet Tissue Procurement Facility. Tenofovir and emtricitabine was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
- preexposure prophylaxis